OMass Therapeutics

OMass Therapeutics is an Oxford-based, private biotech leveraging a unique technology platform centered on native mass spectrometry to discover small molecule drugs against complex targets like membrane protein complexes. The company is advancing a pipeline focused on orphan diseases and immunological conditions, targeting solute carriers, inflammasomes, and GPCRs. Backed by a top-tier investor syndicate, OMass is positioned to tackle inadequately drugged pathways by interrogating targets within their native protein ecosystems, aiming to deliver precision medicines with high biological fidelity.

Integrated platform combining proprietary biochemistry to isolate native protein complexes, native mass spectrometry to analyze interactions, and custom chemistry for drug discovery.

Competes with other biotechs and large pharma pursuing inflammasomes, GPCRs, and solute carriers, but differentiates through its unique native mass spectrometry platform focused on intact protein complexes. Must demonstrate superior compound quality against alternative discovery approaches.